Search

Your search keyword '"A. de la Fuente Burguera"' showing total 42 results
Start Over Author "A. de la Fuente Burguera"
42 results on '"A. de la Fuente Burguera"'

1. P508: REAL LIFE EXPERIENCE USING FRONT-LINE CPX-351 FOR THERAPY-RELATED AND AML-MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY.

Author

T. Bernal, G. Rad, A. de Laiglesia, C. Benavente, A. Garcia Noblejas, D. Garcia Belmonte, R. Riaza, O. Salamero, A. Foncillas, A. Roldán, V. Noriega Concepcion, J. Perez de Oteyza, J. M. Bergua Burgues, S. Lorente de Uña, A. de la Fuente Burguera, M. J. Garcia Perez, J. L. Lopez Lorenzo, P. Martinez, C. Alaez, M. Callejas, C. Martinez Chamorro, J. Rifon Roca, L. Amador Barciela, M. Lopez, K. Gomez Correcha, E. Lavilla Rubiera, M. L. Amigo, F. Vall-Llovera, A. Garrido, M. Garcia Fortes, D. de Miguel Llorente, A. Aules Leonardo, C. Cervero, R. Coll Jorda, M. Perez Encinas, M. Polo Zarzuela, D. Martinez Cuadron, and P. Montesinos

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

3. Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Author

Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, and Pau Montesinos

Subjects
acute myeloid leukemia, clinical observations, intensive chemotherapy, real‐world, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched cohorts of real‐life patients. Methods Retrospective analysis of AML patients treated with CPX‐351 as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes with those observed in a matched cohort among 765 historical patients receiving intensive chemotherapy (IC), all of them reported to the PETHEMA epidemiologic registry. Results Median age of 79 patients treated with CPX‐351 was 67 years old (interquartile range 62–71), 53 were MRC‐AML. The complete remission (CR) rate or CR without recovery (CRi) after 1 or 2 cycles of CPX‐351 was 52%, 60‐days mortality 18%, measurable residual disease

Published
2023
Full Text
View/download PDF

4. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

Author

Shallis, Rory M, Daver, Naval, Altman, Jessica K, Komrokji, Rami S, Pollyea, Daniel A, Badar, Talha, Bewersdorf, Jan P, Bhatt, Vijaya R, de Botton, Stéphane, de la Fuente Burguera, Adolfo, Carraway, Hetty E, Desai, Pinkal, Dillon, Richard, Duployez, Nicolas, El Chaer, Firas, Fathi, Amir T, Freeman, Sylvie D, Gojo, Ivana, Grunwald, Michael R, Jonas, Brian A, Konopleva, Marina, Lin, Tara L, Mannis, Gabriel N, Mascarenhas, John, Michaelis, Laura C, Mims, Alice S, Montesinos, Pau, Pozdnyakova, Olga, Pratz, Keith W, Schuh, Andre C, Sekeres, Mikkael A, Smith, Catherine C, Stahl, Maximilian, Subklewe, Marion, Uy, Geoffrey L, Voso, Maria Teresa, Walter, Roland B, Wang, Eunice S, Zeidner, Joshua F, Žučenka, Andrius, and Zeidan, Amer M

Published
2023
Full Text
View/download PDF

5. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Author

Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, and Manuel Mateo Pérez Encinas

Subjects
leukemia, transcriptome, machine learning, survival, risk, prediction, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2023
Full Text
View/download PDF

6. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

Author

Emilie Bérard, Christoph Röllig, Sarah Bertoli, Arnaud Pigneux, Suzanne Tavitian, Michael Kramer, Hubert Serve, Martin Bornhäuser, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, David Martínez-Cuadrón, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez Arbolí, Cristina Gil, Juan Bergua, Teresa Bernal, Adolfo de la Fuente Burguera, Eric Delabesse, Audrey Bidet, Pierre-Yves Dumas, Pau Montesinos, and Christian Récher

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML patients aged 70 years or older treated with intensive chemotherapy were used to develop a prognostic scoring system. The median follow-up was 50.8 months. In the training set of 636 patients, age, performance status, secondary AML, leukocytosis, and cytogenetics, as well as NPM1 mutations (without FLT3-ITD), were all significantly associated with overall survival, albeit not to the same degree. These factors were used to develop a score that predicts long-term overall survival. Three risk-groups were identified: a lower, intermediate and higher-risk score with predicted 5-year overall survival (OS) probabilities of ≥12% (n = 283, 51%; median OS = 18 months), 3–12% (n = 226, 41%; median OS = 9 months) and

Published
2022
Full Text
View/download PDF

7. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

Author

Récher, Christian, Röllig, Christoph, Bérard, Emilie, Bertoli, Sarah, Dumas, Pierre-Yves, Tavitian, Suzanne, Kramer, Michael, Serve, Hubert, Bornhäuser, Martin, Platzbecker, Uwe, Müller-Tidow, Carsten, Baldus, Claudia D., Martínez-Cuadrón, David, Serrano, Josefina, Martínez-Sánchez, Pilar, Arbolí, Eduardo Rodríguez, Gil, Cristina, Bergua, Juan, Bernal, Teresa, de la Fuente Burguera, Adolfo, Delabesse, Eric, Bidet, Audrey, Pigneux, Arnaud, and Montesinos, Pau

Published
2022
Full Text
View/download PDF

8. Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Author

Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, and Manuel Mateo Pérez Encinas

Subjects
leukemia, transcriptome, machine learning, survival, risk, prediction, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned to low or intermediate risk groups are still high. Therefore, significant room exists for the improvement of AML prognostication. In a previous work, we presented the Stellae-123 gene expression signature, which achieved a high accuracy in the prognostication of adult patients with AML. Stellae-123 was particularly accurate to restratify patients bearing high-risk mutations, such as ASXL1, RUNX1 and TP53. The intention of the present work was to evaluate the prognostic performance of Stellae-123 in external cohorts using RNAseq technology. For this, we evaluated the signature in 3 different AML cohorts (2 adult and 1 pediatric). Our results indicate that the prognostic performance of the Stellae-123 signature is reproducible in the 3 cohorts of patients. Additionally, we evidenced that the signature was superior to the European LeukemiaNet 2017 and the pediatric clinical risk scores in the prediction of survival at most of the evaluated time points. Furthermore, integration with age substantially enhanced the accuracy of the model. In conclusion, Stellae-123 is a reproducible machine learning algorithm based on a gene expression signature with promising utility in the field of AML.

Published
2022
Full Text
View/download PDF

9. A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).

Author

de la Fuente Burguera, Adolfo, primary, Cerchione, Claudio, additional, Scholl, Sebastian, additional, Middeke, Jan Moritz, additional, Nitika, Nitika, additional, Lane, Maureen E, additional, Zhao, Wanying, additional, Angelides, Steven, additional, Roemeling, Reinhard von, additional, and Platzbecker, Uwe, additional

Published
2024
Full Text
View/download PDF

10. Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).

Author

Grommes, Christian, primary, Tun, Han W., additional, de la Fuente Burguera, Adolfo, additional, Dabrowska-Iwanicka, Anna, additional, Regales, Lucia, additional, Zhao, Wanying, additional, Ferrari, Dora, additional, Fowles, Meaghan, additional, Lane, Maureen E, additional, Wang, Catherine, additional, Von Roemeling, Reinhard W., additional, Taszner, Michal, additional, D'angelo, Christopher, additional, and Nowakowski, Grzegorz S., additional

Published
2024
Full Text
View/download PDF

11. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment

Author

Aguareles, Jose, primary, Villares Fernández, Paula, additional, Forné, Carles, additional, Martí-Ballesteros, Eva María, additional, Pradillo Fernández, Virginia, additional, Sotres-Fernandez, Gabriel, additional, de la Fuente-Burguera, Adolfo, additional, Navarro-San Francisco, Carolina, additional, Buzón-Martín, Luis Miguel, additional, García-Delangue, Teresa, additional, Aiello, Francesco Tommaso, additional, Carnevali-Ruiz, Daniel, additional, Lloris, Raquel, additional, Luepke-Estefan, Xavier Erik, additional, López-Martín, José Antonio, additional, Jimeno, José María, additional, García-Casas, Ana, additional, and Guisado-Vasco, Pablo, additional

Published
2024
Full Text
View/download PDF

12. Immunotherapy in Acute Myeloid Leukemia: Where We Stand

Author

Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian, and Antonio Curti

Subjects
acute myeloid leukemia, tolerance, natural killer, immunotherapy, monoclonal antibody, checkpoint inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development, growth and recurrence has gained increasing interest. A better understanding of immunological escape and systemic tolerance induced by AML blasts has been achieved. The extraordinary successes of immune therapies that harness the power of T cells in solid tumors and certain hematological malignancies have provided new stimuli in this area of research. Accordingly, major efforts have been made to develop immune therapies for the treatment of AML patients. The persistence of leukemia stem cells, representing the most relevant cause of relapse, even after allogeneic stem cell transplant (allo-SCT), remains a major hurdle in the path to cure for AML patients. Several clinical trials with immune-based therapies are currently ongoing in the frontline, relapsed/refractory, post-allo-SCT and minimal residual disease/maintenance setting, with the aim to improve survival of AML patients. This review summarizes the available data with immune-based therapeutic modalities such as monoclonal antibodies (naked and conjugated), T cell engagers, adoptive T-cell therapy, adoptive-NK therapy, checkpoint blockade via PD-1/PD-L1, CTLA4, TIM3 and macrophage checkpoint blockade via the CD47/SIRPa axis, and leukemia vaccines. Combining clinical results with biological immunological findings, possibly coupled with the discovery of biomarkers predictive for response, will hopefully allow us to determine the best approaches to immunotherapy in AML.

Published
2021
Full Text
View/download PDF

13. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Author

Mosquera Orgueira, Adrián, primary, Peleteiro Raíndo, Andrés, additional, Díaz Arias, José Ángel, additional, Antelo Rodríguez, Beatriz, additional, López Riñón, Mónica, additional, Cerchione, Claudio, additional, de la Fuente Burguera, Adolfo, additional, González Pérez, Marta Sonia, additional, Martinelli, Giovanni, additional, Montesinos Fernández, Pau, additional, and Pérez Encinas, Manuel Mateo, additional

Published
2023
Full Text
View/download PDF

14. AML-391 WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients

Author

Lopez, Alicia Ortiz, primary, Pau, Montesinos, additional, Gama, Ana Muñoz, additional, Gonzalez, Karla Javier, additional, Valls, Julio Davila, additional, Garcia, Lucia Castilla, additional, Perez, Alicia Roldan, additional, Navascues, Javier Cornago, additional, de los Angeles Foncillas, Maria, additional, Chamorro, Carmen Martinez, additional, Ulrich, Jose Maria Grassa, additional, Oiartzabal, Itziar, additional, Jorda, Rosa Coll, additional, Ordoñez, Sandra Suarez, additional, De Coca, Alfonso Garcia, additional, Lopez, Antonio Diaz, additional, Zoilo, Patricia, additional, Otero, Maria Jose, additional, Tormo, Mar, additional, and de la Fuente Burguera, Adolfo, additional

Published
2023
Full Text
View/download PDF

15. POSTER: AML-391 WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients

Author

Lopez, Alicia Ortiz, primary, Pau, Montesinos, additional, Gama, Ana Muñoz, additional, Gonzalez, Karla Javier, additional, Valls, Julio Davila, additional, Garcia, Lucia Castilla, additional, Perez, Alicia Roldan, additional, Navascues, Javier Cornago, additional, de los Angeles Foncillas, Maria, additional, Chamorro, Carmen Martinez, additional, Ulrich, Jose Maria Grassa, additional, Oiartzabal, Itziar, additional, Jorda, Rosa Coll, additional, Ordoñez, Sandra Suarez, additional, De Coca, Alfonso Garcia, additional, Lopez, Antonio Diaz, additional, Zoilo, Patricia, additional, Otero, Maria Jose, additional, Tormo, Mar, additional, and de la Fuente Burguera, Adolfo, additional

Published
2023
Full Text
View/download PDF

16. POSTER: IBCL-265 Compassionate Use of Plitidepsin in Patients With Non-Hodgkin Lymphoma (NHL) and SARS-CoV-2 Infection

Author

Lopez, Alicia Ortiz, primary, Lou, Elena Saiz, additional, Fernandez, Raquel Lloris, additional, Mendoza, Diego Lopez, additional, de la Oña, Raquel, additional, Estevez, Monica, additional, Iglesias, Rebeca, additional, Zoilo, Patricia, additional, Montalban, Carlos, additional, and de la Fuente Burguera, Adolfo, additional

Published
2023
Full Text
View/download PDF

18. Clinical outcomes after CPX ‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Author

Bernal, Teresa, primary, Moreno, Ainhoa Fernández, additional, de LaIglesia, Almudena, additional, Benavente, Celina, additional, García‐Noblejas, Ana, additional, Belmonte, Daniel García, additional, Riaza, Rosalía, additional, Salamero, Olga, additional, Foncillas, Maria Angeles, additional, Roldán, Alicia, additional, Concepción, Víctor Noriega, additional, González, Laura Llorente, additional, Bergua Burgués, Juan Miguel, additional, Lorente de Uña, Soraya, additional, Rodríguez‐Macías, Gabriela, additional, de la Fuente Burguera, Adolfo, additional, García Pérez, Maria José, additional, López‐Lorenzo, Jose Luis, additional, Martínez, Pilar, additional, Aláez, Concepción, additional, Callejas, Marta, additional, Martínez‐Chamorro, Carmen, additional, Roca, José Rifón, additional, Barciela, Lourdes Amador, additional, Mena Durán, Armando V., additional, Gómez Correcha, Karoll, additional, Lavilla Rubira, Esperanza, additional, Amigo, María Luz, additional, Vall‐llovera, Ferran, additional, Garrido, Ana, additional, García‐Fortes, María, additional, de Miguel Llorente, Dunia, additional, Leonardo, Anastasia Aules, additional, Cervero, Carlos, additional, Jordá, Rosa Coll, additional, Pérez‐Encinas, Manuel M., additional, Zarzuela, Marta Polo, additional, Figuera, Angela, additional, Rad, Guillermo, additional, Martínez‐Cuadrón, David, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

19. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Author

Gail J. Roboz, Karen Yee, Amit Verma, Gautam Borthakur, Adolfo de la Fuente Burguera, Guillermo Sanz, Helai P. Mohammad, Ryan G. Kruger, Natalie O. Karpinich, Geraldine Ferron-Brady, Andre Acusta, Heather Del Buono, Therese Collingwood, Marc Ballas, Arindam Dhar, and Andrew H. Wei

Subjects
Cancer Research, Oncology, Hematology
Published
2021
Full Text
View/download PDF

20. 648TiP Reduction of methotrexate (MTX) levels after glucarpidase in patients with diffuse large b cell lymphoma (DLBCL) at risk of central nervous system (CNS) involvement who receive cycles of HDMTX: An open-label, interventional, non-randomized, phase II, pilot, multicenter study

Author

de la Fuente Burguera, A., primary, Peñalver Parraga, F.J., additional, Cordoba Mascunano, R., additional, Herrera, P., additional, Olave, M.T., additional, Martiniez Chamorro, C., additional, Jarque, I., additional, and Estevez Fernandez, M., additional

Published
2022
Full Text
View/download PDF

21. Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Author

Mosquera Orgueira, Adrián, primary, Peleteiro Raíndo, Andrés, additional, Díaz Arias, José Ángel, additional, Antelo Rodríguez, Beatriz, additional, López Riñón, Mónica, additional, Cerchione, Claudio, additional, de la Fuente Burguera, Adolfo, additional, González Pérez, Marta Sonia, additional, Martinelli, Giovanni, additional, Montesinos Fernández, Pau, additional, and Pérez Encinas, Manuel Mateo, additional

Published
2022
Full Text
View/download PDF

22. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

Author

Bérard, Emilie, primary, Röllig, Christoph, additional, Bertoli, Sarah, additional, Pigneux, Arnaud, additional, Tavitian, Suzanne, additional, Kramer, Michael, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Platzbecker, Uwe, additional, Müller-Tidow, Carsten, additional, Baldus, Claudia D., additional, Martínez-Cuadrón, David, additional, Serrano, Josefina, additional, Martínez-Sánchez, Pilar, additional, Arbolí, Eduardo Rodríguez, additional, Gil, Cristina, additional, Bergua, Juan, additional, Bernal, Teresa, additional, de la Fuente Burguera, Adolfo, additional, Delabesse, Eric, additional, Bidet, Audrey, additional, Dumas, Pierre-Yves, additional, Montesinos, Pau, additional, and Récher, Christian, additional

Published
2022
Full Text
View/download PDF

23. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Author

Roboz, GJ, Yee, K, Verma, A, Borthakur, G, de la Fuente Burguera, A, Sanz, G, Mohammad, HP, Kruger, RG, Karpinich, NO, Ferron-Brady, G, Acusta, A, Del Buono, H, Collingwood, T, Ballas, M, Dhar, A, Wei, AH, Roboz, GJ, Yee, K, Verma, A, Borthakur, G, de la Fuente Burguera, A, Sanz, G, Mohammad, HP, Kruger, RG, Karpinich, NO, Ferron-Brady, G, Acusta, A, Del Buono, H, Collingwood, T, Ballas, M, Dhar, A, and Wei, AH

Published
2022

24. An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms.

Author

Rampal, Raajit, primary, Ramanathan, Sundra, additional, Papayannidis, Cristina, additional, von Bubnoff, Nikolas, additional, del Mar Tormo Díaz, Maria, additional, Vidriales, Maria Belen, additional, de la Fuente Burguera, Adolfo, additional, Masarova, Lucia, additional, Al-Ali, Haifa Kathrin, additional, Lavie, David, additional, Niyongere, Sandrine, additional, Chan, Tiffanie, additional, McGreivy, Jesse S., additional, Rothbaum, Wayne P., additional, Mims, Alice S., additional, and Cluzeau, Thomas, additional

Published
2022
Full Text
View/download PDF

25. Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.

Author

Dohner, Hartmut, primary, Montesinos, Pau, additional, Vives Polo, Susana, additional, Zarzycka, Ewa, additional, Wang, Jianxiang, additional, Bertani, Giambattista, additional, Heuser, Michael, additional, Calado, Rodrigo T., additional, Schuh, Andre C., additional, Yeh, Su-Peng, additional, de la Fuente Burguera, Adolfo, additional, Cerchione, Claudio, additional, Daigle, Scott, additional, Hui, Jianan, additional, Pandya, Shuchi Sumant, additional, Gianolio, Diego A., additional, Recher, Christian, additional, and De Botton, Stéphane, additional

Published
2022
Full Text
View/download PDF

26. P508: REAL LIFE EXPERIENCE USING FRONT-LINE CPX-351 FOR THERAPY-RELATED AND AML-MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY.

Author

Bernal, T., primary, Rad, G., additional, de Laiglesia, A., additional, Benavente, C., additional, Garcia Noblejas, A., additional, Garcia Belmonte, D., additional, Riaza, R., additional, Salamero, O., additional, Foncillas, A., additional, Roldán, A., additional, Noriega Concepcion, V., additional, Perez de Oteyza, J., additional, Bergua Burgues, J. M., additional, Lorente de Uña, S., additional, de la Fuente Burguera, A., additional, Garcia Perez, M. J., additional, Lopez Lorenzo, J. L., additional, Martinez, P., additional, Alaez, C., additional, Callejas, M., additional, Martinez Chamorro, C., additional, Rifon Roca, J., additional, Amador Barciela, L., additional, Lopez, M., additional, Gomez Correcha, K., additional, Lavilla Rubiera, E., additional, Amigo, M. L., additional, Vall-Llovera, F., additional, Garrido, A., additional, Garcia Fortes, M., additional, de Miguel Llorente, D., additional, Aules Leonardo, A., additional, Cervero, C., additional, Coll Jorda, R., additional, Perez Encinas, M., additional, Polo Zarzuela, M., additional, Martinez Cuadron, D., additional, and Montesinos, P., additional

Published
2022
Full Text
View/download PDF

27. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

Author

Audrey Bidet, Hubert Serve, Pierre-Yves Dumas, Carsten Müller-Tidow, Josefina Serrano, Teresa Bernal, Sarah Bertoli, Juan Bergua, Eduardo Rodriguez Arbolí, Uwe Platzbecker, Pilar Martínez-Sánchez, Martin Bornhäuser, Eric Delabesse, Adolfo de la Fuente Burguera, Christian Recher, Arnaud Pigneux, Michael Kramer, Claudia D. Baldus, David Martínez-Cuadrón, Pau Montesinos, Emilie Bérard, Cristina Gil, Christoph Röllig, and Suzanne Tavitian

Subjects
Cancer Research, medicine.medical_specialty, medicine.medical_treatment, EARLY DEATH, NEWLY-DIAGNOSED AML, Intensive chemotherapy, ACUTE MYELOID-LEUKEMIA, REGIMENS, Lower risk, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Long term survival, MANAGEMENT, Humans, Medicine, In patient, VENETOCLAX, Registries, ELDERLY-PATIENTS, AZACITIDINE, Aged, Aged, 80 and over, Chemotherapy, EPIGENETIC THERAPY, business.industry, Significant difference, Myeloid leukemia, Hematology, Patient data, CARE, Leukemia, Myeloid, Acute, Treatment Outcome, Oncology, Azacitidine, business
Abstract

The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients ≥70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7–11.6) and 9.2 months (95% CI: 8.3–10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P

Published
2022

29. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Author

Roboz, Gail J., primary, Yee, Karen, additional, Verma, Amit, additional, Borthakur, Gautam, additional, de la Fuente Burguera, Adolfo, additional, Sanz, Guillermo, additional, Mohammad, Helai P., additional, Kruger, Ryan G., additional, Karpinich, Natalie O., additional, Ferron-Brady, Geraldine, additional, Acusta, Andre, additional, Del Buono, Heather, additional, Collingwood, Therese, additional, Ballas, Marc, additional, Dhar, Arindam, additional, and Wei, Andrew H., additional

Published
2021
Full Text
View/download PDF

30. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

Author

Récher, Christian, primary, Röllig, Christoph, additional, Bérard, Emilie, additional, Bertoli, Sarah, additional, Dumas, Pierre-Yves, additional, Tavitian, Suzanne, additional, Kramer, Michael, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Platzbecker, Uwe, additional, Müller-Tidow, Carsten, additional, Baldus, Claudia D., additional, Martínez-Cuadrón, David, additional, Serrano, Josefina, additional, Martínez-Sánchez, Pilar, additional, Arbolí, Eduardo Rodríguez, additional, Gil, Cristina, additional, Bergua, Juan, additional, Bernal, Teresa, additional, de la Fuente Burguera, Adolfo, additional, Delabesse, Eric, additional, Bidet, Audrey, additional, Pigneux, Arnaud, additional, and Montesinos, Pau, additional

Published
2021
Full Text
View/download PDF

31. EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY

Author

Tomás José González-López, Eva González-Barca, A. Muntanola Prat, F. de la Cruz, J. López Jiménez, E. Campo, María José Casanova, Marta Aymerich, Alejandro Medina, M. J. Terol, A. Jiménez Ubieto, A. Martín García-Sancho, Eva Giné, Ramón García-Sanz, Xavier Setoain, Montserrat Cortés-Romera, A. Marín Niebla, Amanda Rotger, Armando López-Guillermo, and A. De la Fuente Burguera

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Ibrutinib, medicine, Rituximab, Mantle cell lymphoma, business, medicine.drug
Published
2021
Full Text
View/download PDF

32. Immunotherapy in Acute Myeloid Leukemia: Where We Stand

Author

Courtney D. DiNardo, Alessandra Romano, Giuseppe Visani, Naval Daver, Guillermo Garcia-Manero, Giovanni Martinelli, Alessandro Isidori, Antonio Curti, Elias Jabbour, Hagop M. Kantarjian, Adolfo de la Fuente Burguera, Farhad Ravandi, Federica Loscocco, Claudio Cerchione, Tapan M. Kadia, and Marina Konopleva

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, T cell, Review, acute myeloid leukemia, 03 medical and health sciences, 0302 clinical medicine, Immune system, Internal medicine, hemic and lymphatic diseases, medicine, RC254-282, tolerance, business.industry, Myeloid leukemia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, natural killer, Immunotherapy, medicine.disease, Minimal residual disease, Clinical trial, Leukemia, 030104 developmental biology, medicine.anatomical_structure, monoclonal antibody, 030220 oncology & carcinogenesis, immunotherapy, Stem cell, business, checkpoint inhibitors
Abstract

In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development, growth and recurrence has gained increasing interest. A better understanding of immunological escape and systemic tolerance induced by AML blasts has been achieved. The extraordinary successes of immune therapies that harness the power of T cells in solid tumors and certain hematological malignancies have provided new stimuli in this area of research. Accordingly, major efforts have been made to develop immune therapies for the treatment of AML patients. The persistence of leukemia stem cells, representing the most relevant cause of relapse, even after allogeneic stem cell transplant (allo-SCT), remains a major hurdle in the path to cure for AML patients. Several clinical trials with immune-based therapies are currently ongoing in the frontline, relapsed/refractory, post-allo-SCT and minimal residual disease/maintenance setting, with the aim to improve survival of AML patients. This review summarizes the available data with immune-based therapeutic modalities such as monoclonal antibodies (naked and conjugated), T cell engagers, adoptive T-cell therapy, adoptive-NK therapy, checkpoint blockade via PD-1/PD-L1, CTLA4, TIM3 and macrophage checkpoint blockade via the CD47/SIRPa axis, and leukemia vaccines. Combining clinical results with biological immunological findings, possibly coupled with the discovery of biomarkers predictive for response, will hopefully allow us to determine the best approaches to immunotherapy in AML.

Published
2021
Full Text
View/download PDF

33. 648TiP Reduction of methotrexate (MTX) levels after glucarpidase in patients with diffuse large b cell lymphoma (DLBCL) at risk of central nervous system (CNS) involvement who receive cycles of HDMTX: An open-label, interventional, non-randomized, phase II, pilot, multicenter study

Author

A. de la Fuente Burguera, F.J. Peñalver Parraga, R. Cordoba Mascunano, P. Herrera, M.T. Olave, C. Martiniez Chamorro, I. Jarque, and M. Estevez Fernandez

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

34. Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Author

Aspas Requena, Gaspar, Dumas, Pierre Yves, Rodriguez Veiga, Rebeca, Bertoli, Sarah, Gil, Cristina, Simand, Celestine, Ramos-Ortega, Fernando Jesús, Peterlin, Pierre, Serrano, Josefina, Birsen, Rudy, Bernal Del Castillo, Teresa, Tavernier, Emmanuelle, Tormo, Mar, Carre, Martin, Garcia, Maria Jose, Contejean, Adrien, Riaza Grau, Rosalia, Orvain, Corentin, Pérez-Simón, Jose Antonio, Perez Santaolla, Esther, Veronese, Lauren, De Rueda Ciller, Beatriz, Delabesse, Eric, Gutiérrez, Antonio, Mineur, Ariane, De La Fuente Burguera, Adolfo, Guieze, Romain, Pigneux, Arnaud, Montesinos, Pau, Recher, Christian, and Matínez-Cuadrón, David

Published
2023
Full Text
View/download PDF

36. Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia

Author

Hartmut Dohner, Pau Montesinos, Susana Vives Polo, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su-Peng Yeh, Adolfo de la Fuente Burguera, Claudio Cerchione, Scott Daigle, Jianan Hui, Shuchi Sumant Pandya, Diego A. Gianolio, Christian Recher, and Stéphane De Botton

Subjects
Cancer Research, Oncology
Abstract

7042 Background: Ivosidenib (IVO) is a potent oral targeted inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). IVO plus azacitidine (AZA) significantly improved event-free survival (EFS), overall survival and complete remission + partial hematologic recovery rates compared with placebo (PBO) + AZA, in patients (pts) with newly diagnosed IDH1-mutant acute myeloid leukemia (AML) in the Phase 3 AGILE trial (NCT03173248). Here we report blood count recovery results from the AGILE trial. Methods: Pts were randomized 1:1 to IVO 500 mg QD + AZA 75 mg/m2 SC or IV for 7 days in 28-day cycles (n = 72), or PBO+AZA (n = 74). Red blood cell (RBC)/platelet transfusion history were assessed at screening and follow-up. Bone marrow (BM) and peripheral blood samples were obtained at screening, and during weeks 9, 17, 25, 33, 41, 53, and every 24 weeks thereafter, and at end of treatment and during EFS follow up. Samples were analyzed at each local site according to ICSH guidelines. Results: In the IVO+AZA and PBO+AZA arms, 4.2% and 5.5% of pts, respectively, received concomitant granulocyte colony-stimulating factor. Hemoglobin levels steadily increased from baseline at a similar rate in both treatment arms. Mean platelet count recovered from baseline values in the IVO+AZA and PBO+AZA arms (71.0 and 92.6 x 109/L, respectively) as early as week 9 of treatment (171.1 and 155.1 x 109/L, respectively) and continued to steadily increase thereafter in the treated population. In pts receiving IVO+AZA, mean neutrophil counts rapidly increased from baseline (0.99 x 109/L) to week 2 (2.05 x 109/L) and week 5 (4.07 x 109/L), and then generally stabilized to within the normal range to study end (last available cycle value; ̃2.0 x 109/L). Mean neutrophil counts initially declined with PBO+AZA before slowly recovering to near-normal levels after 36-40 weeks. The increased blood counts were accompanied by a rapid decrease in the mean BM blast percentage from 54.8% at baseline to 12.0% and 7.2% at week 9 and 17, respectively, in IVO+AZA treated patients and were maintained for 149 weeks. The decline in BM blasts was slower in the PBO+AZA arm (53.7%, 34.6% and 19.6% at baseline, week 9 and week 17, respectively). Among patients who were RBC/platelet transfusion-dependent at baseline (̃54.0% in both groups), 46.2% in the IVO+AZA group achieved RBC/platelet transfusion independence compared with 17.5% in the PBO+AZA arm (1-sided p = 0.0032). Additionally, fewer adverse events of febrile neutropenia (28.2% vs 34.2%) and infections (28.2% vs 49.3%) were reported in the IVO+AZA arm compared to the PBO+AZA arm. Conclusions: IVO+AZA demonstrated a significant clinical benefit compared with PBO+AZA and this sub-analysis demonstrated a rapidly improved recovery of blood counts and a reduced dependence on RBC and/or platelet transfusion. Moreover, rates of febrile neutropenia and infections were reduced with IVO+AZA. Clinical trial information: NCT03173248.

Published
2022
Full Text
View/download PDF

37. EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY

Author

Giné, E., primary, De la Cruz, F., additional, Ubieto, A. Jiménez, additional, Jiménez, J. López, additional, García‐Sancho, A. Martín, additional, Terol, M. J., additional, González‐Barca, E., additional, Casanova, M., additional, De la Fuente Burguera, A., additional, Niebla, A. Marín, additional, Prat, A. Muntanola, additional, González‐López, T. J., additional, Aymerich, M., additional, Setoain, X., additional, Cortés‐Romera, M., additional, Rotger, A., additional, Medina, A., additional, García‐Sanz, R., additional, Campo, E., additional, and López‐Guillermo, A., additional

Published
2021
Full Text
View/download PDF

38. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

Author

Ya-Zhen Qin, Daobin Zhou, Jian Xiang Wang, Chen-Hua Yan, Chor Sang Chim, Frederick B. Hagemeister, Keiya Ozawa, Swaminathan P. Iyer, Yu Hu, Sattava Neelapu, Michael Wang, Jin Lu, Allen Eng Juh Yeoh, Jian Hou, Surapol Issaragrisil, Depei Wu, Simrit Parmar, Jianyong Li, Xiao-Jun Huang, Vikram Mathews, Zhijian Xiao, Kai-Yan Liu, Jiong Hu, Borje S. Andersson, Richard E. Champlin, Qian Jiang, Daryl Tan, Suradej Hongeng, Robert Z. Orlowski, Raymond S.M. Wong, Miguel A. Sanz, Zonghong Shao, Lian Sheng Zhang, Adolfo de la Fuente Burguera, Stephen P. Mulligan, Pankaj Malhotra, Dong-Wook Kim, Jason R. Westin, David Ritchie, Elizabeth J. Shpall, Stephen Kornblau, and Yu Wang

Subjects
Warrant, medicine.medical_specialty, China, Asia, Concordance, Best practice, lymphoma, Medical Oncology, 03 medical and health sciences, 0302 clinical medicine, Beijing, Surveys and Questionnaires, medicine, Humans, General knowledge, Practice Patterns, Physicians', Intensive care medicine, Geographic difference, Medical education, business.industry, hematology, leukemia, Transplantation, myeloma, Oncology, 030220 oncology & carcinogenesis, Hematologic Neoplasms, Clinical Research Paper, business, 030215 immunology
Abstract

This report serves as a snapshot of the state-of-knowledge in the Asia Pacific (APAC) Hematology Oncology community, and establishes a baseline for longitudinal investigations to follow changes in best practices over time. The objective of this study was to understand the approach to hematologic diseases, common standards of care and best practices, issues that remain controversial or debated, and educational or resource gaps that warrant attention. We used mobile application to disseminate and distribute questionnaires to delegates during the 6th international hematologic malignancies conference hosted by the APAC Hematology Consortium at Beijing, China. User responses were collected in an anonymous fashion. We report survey results in two ways: the overall responses, and responses as stratified between Chinese physicians and "Other" represented nationalities. Overall geographical concordance in survey responses was positive and strong. Perhaps more interesting than instances of absolute agreement, these data provide a unique opportunity to identify topics in which physician knowledge or opinions diverge. We assigned questions from all modules to broad categories of: patient information; diagnosis; treatment preference; transplantation; and general knowledge/opinion. On average, we observed a geographic difference of 15% for any particular answer choice, and this was fairly constant across survey modules. These results reveal utility and need for widespread and ongoing initiatives to assess knowledge and provide evidence-based education in real time. The data will be made more valuable by longitudinal participation, such that we can monitor changes in the state of the art over time.

Published
2017

40. PB1747 ASSESSMENT OF FLT3 MUTATION IN ACUTE MYELOID LEUKEMIA: RESULTS OF A SPANISH DELPHI PANEL SURVEY

Author

Miguel A. Sanz, Marta Pratcorona, Maite Gómez-Casares, Jose Amilcar Rizzo Sierra, A. De la Fuente Burguera, Josefina Serrano, Maria-Jose Calasanz, A. Jimenez Velasco, Eva Barragán, and J. Esteve

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Flt3 mutation, medicine, Delphi method, Myeloid leukemia, Hematology, business
Published
2019
Full Text
View/download PDF

41. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

Author

Huang, Xiao Jun, primary, Liu, Kaiyan, additional, Ritchie, David, additional, Andersson, Borje, additional, Lu, Jin, additional, Hou, Jian, additional, de la Fuente Burguera, Adolfo, additional, Wang, JianXiang, additional, Yeoh, Allen, additional, Yan, Chenhua, additional, Zhou, Daobin, additional, Tan, Daryl, additional, Kim, Dong Wook, additional, Wu, Depei, additional, Shpall, Elizabeth, additional, Kornblau, Stephen, additional, Neelapu, Sattava, additional, Hongeng, Suradej, additional, Li, Jianyong, additional, Hu, Jiong, additional, Zhang, Lian Sheng, additional, Wang, Michael, additional, Malhotra, Pankaj, additional, Jiang, Qian, additional, Qin, Yazhen, additional, Wong, Raymond, additional, Champlin, Richard, additional, Hagemeister, Frederick, additional, Westin, Jason, additional, Iyer, Swaminathan, additional, Mathews, Vikram, additional, Wang, Yu, additional, Hu, Yu, additional, Xiao, Zhijian, additional, Shao, Zonghong, additional, Orlowski, Robert Z., additional, Chim, Chor Sang, additional, Mulligan, Stephen, additional, Sanz, Miguel, additional, Ozawa, Keiya, additional, Parmar, Simrit, additional, and Issaragrisil, Surapol, additional

Published
2017
Full Text
View/download PDF

42. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

Author

Orgueira, Adrián Mosquera, Raíndo, Andrés Peleteiro, Díaz Arias, José Ángel, Rodríguez, Beatriz Antelo, Riñón, Mónica López, Cerchione, Claudio, de la Fuente Burguera, Adolfo, González Pérez, Marta Sonia, Martinelli, Giovanni, Fernández, Pau Montesinos, and Pérez Encinas, Manuel Mateo

Subjects
ACUTE myeloid leukemia, GENE expression
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results